ALG11 inhibitors belong to a distinct chemical class of compounds that play a crucial role in the field of glycobiology, specifically in the realm of protein glycosylation. Glycosylation is a fundamental post-translational modification process in which complex sugar molecules, or glycans, are attached to proteins, thereby influencing their structure, stability, and function. ALG11 inhibitors are a group of chemical compounds designed to target and disrupt the function of ALG11, a key enzyme involved in the early stages of N-linked glycosylation, a specific type of glycosylation that occurs in the endoplasmic reticulum of eukaryotic cells.
ALG11, short for Asparagine-linked glycosylation 11, is an enzyme that catalyzes the transfer of a specific glycan precursor onto nascent proteins during N-linked glycosylation. This enzymatic step is essential for the proper folding and functioning of glycoproteins, which are involved in various cellular processes, including cell-cell communication, signal transduction, and immune response. ALG11 inhibitors work by interfering with the activity of this enzyme, leading to the accumulation of under-glycosylated or misfolded proteins in the endoplasmic reticulum. This disruption can have a profound impact on cellular homeostasis and has implications in various biological contexts, such as protein quality control and cellular stress responses.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | ¥2008.00 ¥7311.00 ¥18694.00 | 3 | |
伦伐替尼通过与ALK1的ATP结合位点结合来抑制ALK1,阻止SMAD1/5等下游信号蛋白的磷酸化,从而抑制血管生成和肿瘤生长。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | ¥632.00 ¥2933.00 ¥4693.00 | 129 | |
索拉非尼通过靶向多种激酶(包括 ALK1、Raf-1 和 VEGFR-2)抑制 ALK1 信号传导,从而减少血管生成和肿瘤生长。 | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | ¥2177.00 ¥5754.00 ¥12094.00 | 4 | |
舒尼替尼可抑制 ALK1 和其他激酶,阻止 SMAD1/5 等下游靶点的磷酸化,抑制血管生成和肿瘤进展。 | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | ¥1038.00 ¥2302.00 | 1 | |
卡博替尼以 ALK1、VEGFR-2 和 MET 为靶点,通过抑制 ALK1 磷酸化和下游信号通路,减少血管生成和肿瘤生长。 | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | ¥3610.00 ¥4851.00 | 3 | |
瑞戈非尼是一种多激酶抑制剂,以 ALK1、VEGFR-2 等为靶点,通过阻断 ALK1 介导的信号传导来破坏血管生成和肿瘤生长。 | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | ¥1433.00 ¥2008.00 | 2 | |
帕唑帕尼(Pazopanib)可抑制 ALK1 和 VEGFR-2,通过破坏 ALK1 依赖性信号通路,减少血管生成和肿瘤生长。 | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | ¥2031.00 ¥3554.00 | 2 | |
Nintedanib 可抑制 ALK1、血管内皮生长因子受体(VEGFR)和表皮生长因子受体(PDGFR),通过干扰 ALK1 介导的信号转导抑制血管生成并抑制肿瘤生长。 | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | ¥1941.00 ¥10876.00 | 2 | |
泊纳替尼是一种多激酶抑制剂,靶向 ALK1 和其他激酶,通过阻断 ALK1 磷酸化和下游通路抑制血管生成和肿瘤生长。 | ||||||
Vandetanib | 443913-73-3 | sc-220364 sc-220364A | 5 mg 50 mg | ¥1884.00 ¥15265.00 | ||
Vandetanib 可抑制 ALK1 和 VEGFR-2,通过干扰 ALK1 介导的信号转导破坏血管生成并抑制肿瘤进展。 | ||||||
Tivozanib | 475108-18-0 | sc-475339 | 5 mg | ¥3610.00 | ||
Tivozanib 是一种血管内皮生长因子受体抑制剂,可通过减少血管内皮生长因子诱导的血管生成间接影响 ALK1 信号,从而影响肿瘤生长。 |